Hong Kong-listed Chinese healthcare firm Golden Meditech Holdings (SEHK: 00801) and The University of Texas at MD Anderson Cancer Center have announced the creation of Cellenkos, a start-up focused on umbilical cord blood derived T-regulatory (T-reg) cellular therapies.
Cellenkos, to be based in Houston, is funded with an initial investment of $10 million, with warrants to purchase a further $10 million worth of shares by Golden Meditech and an independent strategic investor.
The agreement covers technologies arising from the laboratory investigations of Simrit Parmar, associate professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze